An observational study in Psoriasis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in United States. Open to female participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-11-29.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, reaches primary completion later than 1 of the 13 other live ones, and was the 36th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 40+
Bristol-Myers Squibb · Sites in United States
Women only · Healthy volunteers
Bristol-Myers Squibb · Sites in France, Switzerland
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 15 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 9 · Phase 4 3
First in 1995; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 833 is above the median of 200 across 408 observational studies indexed under Psoriasis.
Median enrollment 131 across the 28 interventional studies, 528 across the 14 observational. Of the 28 that completed or were terminated, 10 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
3 of the studies in Psoriasis by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710470Bristol-Myers SquibbA Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring | 2027-01-31 |
| NCT06512337Bristol-Myers SquibbA Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China | 2027-03-11 |
| NCT07256015Bristol-Myers SquibbDeucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | 2027-07-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.
This study will include women aged 15 through 50 years with psoriasis who become pregnant (based on their estimated date of conception) from 09-Sep-2022 through 31-Oct-2026 that have been identified in the Optum Research Database (ORD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants exposed to deucravacitinib for the full pregnancy duration
Drug: Deucravacitinib
Participants exposed to deucravacitinib for the first trimester
Drug: Deucravacitinib
Participants exposed to deucravacitinib for the first 20 weeks of gestation
Drug: Deucravacitinib
Participants exposed to other systemic psoriasis medications for the full pregnancy duration
Drug: Systemic psoriasis medications
Participants exposed to other systemic psoriasis medications for the first trimester
Drug: Systemic psoriasis medications
Participants exposed to other systemic psoriasis medications for the first 20 weeks of gestation
Drug: Systemic psoriasis medications
Participants not exposed to any systemic medications for the full pregnancy duration
Other: No systemic medications
Participants not exposed to any systemic medications during the first trimester
Other: No systemic medications
Participants not exposed to any systemic medications during the first 20 weeks of gestation
Other: No systemic medications
As per product label
As per product label
Participants not exposed to any systemic medications
Number of infants born with Major Congenital Malformations (MCMs)
MCMs defined as a structural abnormality with surgical, medical, or cosmetic importance (excluding chromosomal abnormalities or physiological features due to complications of prematurity, such as cryptorchidism, inguinal hernia, or isolated patent ductus arteriosus in infants born less than 37 weeks of gestation)
Time frame: Up to 12 months after birth or date of health plan disenrollment
Pregnancy outcomes
Incidence of the following pregnancy outcomes: spontaneous abortion, induced abortion, ectopic pregnancy, stillbirth, pre-eclampsia, eclampsia and gestational diabetes
Time frame: Up to 9 months or date of health plan disenrollment
Infant outcomes
Incidence of the following infant outcomes: small for gestational age, large for gestational age, low birthweight, preterm birth, serious or opportunistic infections, postnatal growth deficiency, infant developmental deficiency, neonatal hospitalization, and infant/neonatal/perinatal death
Time frame: Up to 12 months after birth or date of health plan disenrollment
Plan to share: No
Started Aug 2024 (actual). Primary completion is estimated for Jan 2027, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.